Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN versus TOLECTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN versus TOLECTIN.
NAPROXEN vs TOLECTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
250-500 mg orally twice daily; maximum 1.5 g/day. For extended-release: 750-1000 mg orally once daily.
400-600 mg orally three times daily; maximum 1.8 g/day.
None Documented
None Documented
Terminal elimination half-life 12-17 hours (mean 14 hours); permits twice-daily dosing. Half-life prolonged in elderly and hepatic impairment.
Clinical Note
moderateNaproxen + Gatifloxacin
"Naproxen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNaproxen + Rosoxacin
"Naproxen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNaproxen + Levofloxacin
"Naproxen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNaproxen + Trovafloxacin
"Naproxen may increase the neuroexcitatory activities of Trovafloxacin."
Terminal half-life approximately 5-6 hours; clinical context: dosing every 6-8 hours required due to relatively short half-life; steady-state achieved within 24-30 hours.
Primarily renal (95% as unchanged naproxen and 6-O-desmethylnaproxen); <5% fecal via biliary excretion.
Renal (90-95% as unchanged drug and metabolites, primarily glucuronide conjugates); biliary/fecal (minor, <5%).
Category D/X
Category C
NSAID
NSAID